Search

Your search keyword '"Retz, M"' showing total 698 results
Start Over Author "Retz, M"
698 results on '"Retz, M"'

9. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

15. Safety and efficacy of 177Lu-PSMA-I&T Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer: Report on eighty patients over age eighty

Author

Grigorascu, S., additional, Tauber, R., additional, Knorr, K., additional, Retz, M., additional, Rauscher, I., additional, Hansen, K., additional, D’Alessandria, C., additional, Wester, H. J., additional, Gschwend, J., additional, Weber, W. A., additional, Eiber, M., additional, and Langbein, T., additional

Published
2023
Full Text
View/download PDF

17. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Author

Antonarakis, E.S., Park, S.H., Goh, J.C., Shin, S.J., Lee, J.L., Mehra, N., McDermott, R., Sala-Gonzalez, N., Fong, P.C., Greil, R., Retz, M., Sade, J.P., Yanez, P., Huang, Y.H., Begbie, S.D., Gafanov, R.A., Santis, M. de, Rosenbaum, E., Kolinsky, M.P., Rey, F., Chiu, K.Y., Roubaud, G., Kramer, G., Sumitomo, M., Massari, F., Suzuki, H., Qiu, P., Zhang, J., Kim, J., Poehlein, C.H., Yu, E.Y., Antonarakis, E.S., Park, S.H., Goh, J.C., Shin, S.J., Lee, J.L., Mehra, N., McDermott, R., Sala-Gonzalez, N., Fong, P.C., Greil, R., Retz, M., Sade, J.P., Yanez, P., Huang, Y.H., Begbie, S.D., Gafanov, R.A., Santis, M. de, Rosenbaum, E., Kolinsky, M.P., Rey, F., Chiu, K.Y., Roubaud, G., Kramer, G., Sumitomo, M., Massari, F., Suzuki, H., Qiu, P., Zhang, J., Kim, J., Poehlein, C.H., and Yu, E.Y.

Abstract

Contains fulltext : 295958.pdf (Publisher’s version ) (Open Access), PURPOSE: There is an unmet need for therapeutic options that prolong survival for patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) for biomarker-unselected, previously treated mCRPC. METHODS: Eligible participants had mCRPC that progressed on or after abiraterone or enzalutamide (but not both) and docetaxel. Participants were randomly assigned (2:1) to pembrolizumab plus olaparib or NHA (abiraterone or enzalutamide). The dual primary end points were radiographic progression-free survival (rPFS) by blinded independent central review per Prostate Cancer Working Group-modified RECIST 1.1 and overall survival (OS). Time to first subsequent therapy (TFST) was a key secondary end point. Safety and objective response rate (ORR) were secondary end points. RESULTS: Between May 30, 2019, and July 16, 2021, 529 participants were randomly assigned to pembrolizumab plus olaparib and 264 to NHA. At final rPFS analysis, median rPFS was 4.4 months (95% CI, 4.2 to 6.0) with pembrolizumab plus olaparib and 4.2 months (95% CI, 4.0 to 6.1) with NHA (hazard ratio [HR], 1.02 [95% CI, 0.82 to 1.25]; P = .55). At final OS analysis, median OS was 15.8 months (95% CI, 14.6 to 17.0) and 14.6 months (95% CI, 12.6 to 17.3), respectively (HR, 0.94 [95% CI, 0.77 to 1.14]; P = .26). At final TFST analysis, median TFST was 7.2 months (95% CI, 6.7 to 8.1) versus 5.7 months (95% CI, 5.0 to 7.1), respectively (HR, 0.86 [95% CI, 0.71 to 1.03]). ORR was higher with pembrolizumab plus olaparib versus NHA (16.8% v 5.9%). Grade ≥3 treatment-related adverse events occurred in 34.6% and 9.0% of participants, respectively. CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occu

Published
2023

33. Muskelinvasives Urothelkarzinom der Harnblase

Author

Autenrieth, M., Nawroth, R., Semmlack, S., Gschwend, J.E., and Retz, M.

Abstract

Zusammenfassung: Die Detektion von Lymphknotenmetastasen ist ein wichtiger prognostischer Faktor für das progressionsfreie Überleben von Harnblasenkarzinompatienten. Die Zystektomiepatienten werden im Rahmen der LEA-Studie (AUO AB 25/02) randomisiert und erhalten entweder eine eingeschränkte (obturatorische und externe iliakale Lymphknoten) oder eine ausgedehnte Lymphadenektomie (Lymphknoten zwischen Beckenboden und Abgang der A. mesenterica inferior). Ziel unserer Untersuchung ist eine sensitive und spezifische Detektion von Lymphknotenmetastasen, die durch die klassische Histopathologie nicht erkannt werden. Methodisch analysieren wir die Expression einer Genmarkerkombination von Cytokeratin-20 (CK-20), Uroplakin-II (UP-II), Muzin 2 (MUC2) und Muzin 7 (MUC7) mittels RT-PCR (reverse transcriptase-polymerase chain reaction), wodurch wir eine zuverlässige Aussage über das Auftreten von okkulten disseminierten Tumorzellen erhalten. Von 19 Zystektomiepatienten wurden bisher 315 Lymphknoten molekularbiologisch auf CK-20 untersucht. In 93 Lymphknoten konnte eine Expression von CK-20 nachgewiesen werden. Hiervon waren lediglich 18 Lymphknoten in der Histopathologie positiv. Über ein Drittel der CK-20-positiven Lymphknotenmetastasen befanden sich außerhalb des eingeschränkten Lymphadenektomiefeldes. „Skip lesions“ wurden nicht nachgewiesen. Die Nachsorgedaten werden zeigen, ob ein Zusammenhang zwischen dem Nachweis der von uns getesteten molekularbiologischen Epithelmarker und dem progressionsfreien Überleben besteht.

Published
2024
Full Text
View/download PDF

34. EMMPRIN (CD147)

Author

Nawroth, R., Stöhr, R., Hartmann, A., Gschwend, J.E., and Retz, M.

Abstract

Zusammenfassung: EMMPRIN (CD147) ist ein Zelloberflächenprotein und wird von Karzinomzellen verschiedener Tumorentitäten überexprimiert, wobei die Intensität der Expression mit der Tumorprogression korreliert. In Patienten mit lokal fortgeschrittenem Harnblasenkarzinom ist EMMPRIN ein unabhängiger prognostischer Marker für das Gesamtüberleben. In einer klinischen Phase-II-Studie wurden mit spezifischen Antikörpern gegen EMMPRIN erste Erfolg versprechende Therapieansätze an Leberkarzinompatienten erreicht. Aufbauend auf diesen Daten charakterisieren wir in unserem Forschungsprojekt das Potential von EMMPRIN als ein neues Zielmolekül bei der Behandlung des Harnblasenkarzinoms.

Published
2024
Full Text
View/download PDF

42. 1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study

Author

Yu, E.Y., primary, Park, S.H., additional, Goh, J.C.H., additional, Shin, S.J., additional, Mehra, N., additional, McDermott, R., additional, Sala Gonzalez, M.A., additional, Fong, P.C., additional, Greil, R., additional, Retz, M., additional, Sade, J.P., additional, Huang, Y-H., additional, Begbie, S., additional, Rey, F., additional, Kramer, G., additional, Suzuki, H., additional, Zhang, J., additional, Kim, J., additional, Poehlein, C.H., additional, and Antonarakis, E.S., additional

Published
2022
Full Text
View/download PDF

44. 1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)

Author

Koshkin, V.S., primary, Powles, T.B., additional, Iyer, G., additional, Loriot, Y., additional, Drakaki, A., additional, Duran Martinez, I., additional, De Santis, M., additional, Retz, M., additional, Jain, R.K., additional, Chan, S., additional, Ichimaru, M., additional, and Galsky, M.D., additional

Published
2022
Full Text
View/download PDF

45. LBA75 RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results

Author

Schmid, S.C., primary, Schiller, K., additional, Lewerich, J., additional, Seitz, A.K., additional, Sauter, A., additional, Koll, F., additional, Beckert, F., additional, Korn, P., additional, Maisch, P., additional, Rödel, C., additional, Flentje, M., additional, Wiegel, T., additional, Combs, S., additional, Zengerling, F., additional, Bolenz, C., additional, Kuebler, H., additional, Gschwend, J., additional, and Retz, M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results